In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales
The emergence of metallo-β-lactamase (MBL)-producing Enterobacterales, mainly New Delhi metallo-β-lactamase (NDM), represents a clinical threat due to the limited therapeutic alternatives. Aztreonam (AZT) is stable to MBLs, but most MBL-producing Enterobacterales isolates usually co-harbour other β-lactamases that confer resistance to AZT and, consequently, its use is restricted in these isolates. We compared the ability of sulbactam (SUL), tazobactam (TAZ), clavulanic acid (CLA) and avibactam (AVI) to restore the AZT activity in MBL-producing AZT-resistant Enterobacterales isolates. A collection of 64 NDM-producing AZT-resistant Enterobacterales from five hospitals in Buenos Aires city, Argentina, were studied during the period July–December 2020. MICs were determined using the agar dilution method with Mueller–Hinton agar according to Clinical and Laboratory Standards Institute (CLSI) recommendations. AVI, SUL and TAZ were used at a fixed concentration of 4 mg l−1, whereas CLA was used at a fixed concentration of 2 mg l−1. A screening method based on disc diffusion to evaluate this synergy was also conducted. Detection of blaKPC, blaOXA, blaNDM, blaVIM,blaCTXM-1, blaPER-2 and blaCIT was performed by PCR. The AZT-AVI combination restored the AZT activity in 98.4 % of AZT-resistant strains, whereas CLA, TAZ and SUL did so in 70.3, 15.6 and 12.5 %, respectively, in isolates co-harbouring extended-spectrum β-lactamases, but were inactive in isolates harbouring AmpC-type enzymes and/or KPC. The synergy screening test showed an excellent negative predictive value to confirm the absence of synergy, but positive results should be confirmed by a quantitative method. The excellent in vitro performance of the AZT-CLA combination represents a much more economical alternative to AZT-AVI, which could be of use in the treatment of MBL-producing, AZT-resistant Enterobacterales.
DortetL, PoirelL, NordmannP. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int2014; 2014:249856 [View Article] [PubMed]
CantónR, GijónD, Ruiz-GarbajosaP. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. Curr Opin Crit Care2020; 26:433–441 [View Article] [PubMed]
FalconeM, DaikosGL, TiseoG, BassoulisD, GiordanoC et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Clin Infect Dis2020; 19:1871–1878 [View Article]
ZouC, WeiJ, ShanB, ChenX, WangD et al.In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant enterobacteriaceae isolates collected from three secondary hospitals in southwest china between 2018 and 2019. Infect Drug Resist2020; 13:3563–3568 [View Article] [PubMed]
FalconeM, PatersonD. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother2016; 7:2713–2722 [View Article]
EmeraudC, EscautL, BouclyA, FortineauN, BonninRA et al. Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-β-lactamase-producing gram-negative bacteria. Antimicrob Agents Chemother2019; 63:e00010-19 [View Article] [PubMed]
CLSIMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, standard M07, 11th edn Wayne, PA: Clinical and Laboratory Standards Institute; 2018
BiagiM, WuT, LeeM, PatelS, ButlerD et al. Searching for the optimal treatment for metallo- and serine-β-lactamase producing enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob Agents Chemother2019; 63:e01426–19 [View Article] [PubMed]
RuggieroM, Papp-WallaceKM, BrunettiF, BarnesMD, BonomoRA et al. Structural insights into the inhibition of the extended-spectrum β-lactamase per-2 by avibactam. Antimicrob Agents Chemother2019; 63:e00487-19 [View Article] [PubMed]
QuinterosM, RadiceM, GardellaN, RodriguezMM, CostaN et al. Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother2003; 47:2864–2867 [View Article] [PubMed]
XuQ, FuY, JiJ, DuX, YuY. In vitro effect of the combination of aztreonam and amoxicillin/clavulanic acid against carbapenem-resistant gram-negative organisms producing metallo-β-lactamase. Infect Drug Resist2021; 14:833–839 [View Article] [PubMed]
Rocha-SantosG, CubaGT, CayôR, StrelingAP, NodariCS et al. In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains. Diagn Microbiol Infect Dis2021; 100:115343 [View Article] [PubMed]
BiagiM, LammD, MeyerK, VialichkaA, JurkovicM et al. Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother2020; 64:e00297–20 [View Article] [PubMed]
GarcíaJ, NastroM, CejasD, SantanaG, MancinoMB et al. Emergence of ceftazidime/avibactam resistance in KPC-8-producing Klebsiella pneumoniae in South America. Clin Microbiol Infect2020; 26:1264–1265 [View Article] [PubMed]
In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales